Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression

2019 ◽  
Vol 250 ◽  
pp. 199-203 ◽  
Author(s):  
Thomas Kim ◽  
Colin Xu ◽  
Jay D. Amsterdam
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Relative Effectiveness ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

scholarly journals Development of new antidepressants

1997 ◽  
Vol 3 (1) ◽  
pp. 46-51 ◽  
Author(s):  
Eleni Palazidou
Keyword(s):  
Monoamine Oxidase ◽  
Turning Point ◽  
Monoamine Oxidase Inhibitor ◽  
Depressive Illness ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Antituberculous Drugs ◽  
One Year

The development of the first effective antidepressants in the late 1950s marked a turning point in the treatment of depressive illness. In 1957 the monoamine oxidase inhibitor (MAOI) iproniazid was discovered by chance, while searching for new antituberculous drugs. One year later the tricyclic antidepressant (TCA) imipramine was introduced, having been developed originally as an antipsychotic. A number of other drugs were subsequently added to these two groups of antidepressants, which dominated the field for the next three decades.

Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis

2020 ◽  
Vol 32 (5-6) ◽  
pp. 477-490 ◽  
Author(s):  
Ben Carter ◽  
Rebecca Strawbridge ◽  
Muhammad Ishrat Husain ◽  
Brett D. M. Jones ◽  
Roxanna Short ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Relative Effectiveness ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression
Sign in / Sign up

Export Citation Format

Share Document